Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4633559
Max Phase: Preclinical
Molecular Formula: C29H39NO5
Molecular Weight: 481.63
Molecule Type: Unknown
Associated Items:
ID: ALA4633559
Max Phase: Preclinical
Molecular Formula: C29H39NO5
Molecular Weight: 481.63
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C[C@@H]1CC[C@@H]2[C@@H]1[C@H](OC(=O)/C=C/c1ccccc1)[C@]1(C3CCCCC3)C[C@@H](NC(=O)CO)[C@@]2(C)O1
Standard InChI: InChI=1S/C29H39NO5/c1-19-13-15-22-26(19)27(34-25(33)16-14-20-9-5-3-6-10-20)29(21-11-7-4-8-12-21)17-23(28(22,2)35-29)30-24(32)18-31/h3,5-6,9-10,14,16,19,21-23,26-27,31H,4,7-8,11-13,15,17-18H2,1-2H3,(H,30,32)/b16-14+/t19-,22-,23-,26-,27+,28+,29-/m1/s1
Standard InChI Key: JATHZHDQYHORSZ-OXBSAGKHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 481.63 | Molecular Weight (Monoisotopic): 481.2828 | AlogP: 4.26 | #Rotatable Bonds: 6 |
Polar Surface Area: 84.86 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.22 | CX Basic pKa: | CX LogP: 4.52 | CX LogD: 4.52 |
Aromatic Rings: 1 | Heavy Atoms: 35 | QED Weighted: 0.47 | Np Likeness Score: 1.58 |
1. Wu Z, Suppo JS, Tumova S, Strope J, Bravo F, Moy M, Weinstein ES, Peer CJ, Figg WD, Chain WJ, Echavarren AM, Beech DJ, Beutler JA.. (2020) Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition., 11 (9): [PMID:32944138] [10.1021/acsmedchemlett.0c00186] |
Source(1):